← 產業報告目錄

Osteoporosis Market Research Report by Drug Class (Branded, Generic), By Type (Bisphosphonates, Parathyroid Hormone Therapy, RANK Ligand (RANKL) Inhibitors, Selective Oestrogen Receptor Modulators (SERMs), Calcitonin, Sclerostin, Inhibitors, and Others.), By Route of Administration (Oral, Injectable, and Others), By Application (Primary Osteoporosis, Secondary Osteoporosis, and Others), By Gender (Male, Female), By Mechanism Action (Antiresorptive and Anabolic), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online), By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) Forecast till 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2026-05-02頁數 232報告編號 MRFRPharma1841CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

The Global Osteoporosis Market was valued at USD 14,956.06 million in 2025 and is projected to reach USD 28,335.59 million by 2035. The market is anticipated to expand at a CAGR of 6.51% during the forecast period, driven by the rising aging population and increasing prevalence of bone-related disorders worldwide. Rising Awareness of Postmenopausal Bone Health One of the key reasons fueling global osteoporosis market is women becoming aware of their risk of bone loss post menopause as a result of which a major campaign, health screening and early diagnosis program are being rolled out globally to adopt more preventive treatment and therapy for the disease. Segment-Wise Market Overview By Drug Class • Branded: Premium therapies with strong physician preference. • Generic: Cost-effective treatments driving wider patient access. By Type • Bisphosphonates: Widely prescribed for preventing bone density loss. • Parathyroid Hormone Therapy: Stimulates new bone formation effectively. • RANK Ligand (RANKL) Inhibitors: Reduces bone resorption and fracture risks. • Selective Oestrogen Receptor Modulators (SERMs): Supports bone health in postmenopausal women. • Calcitonin: Helps regulate calcium and reduce bone loss. • Sclerostin Inhibitors: Promotes rapid bone formation and strength. • Others: Emerging therapies expanding osteoporosis treatment possibilities. By Route of Administration • Oral: Convenient option for long-term osteoporosis management. • Injectable: Preferred for severe and advanced osteoporosis cases. • Others: Alternative delivery methods improving treatment flexibility. By Application • Primary Osteoporosis: Most common age-related bone disorder segment. • Secondary Osteoporosis: Linked with underlying diseases or medications. • Others: Includes rare and condition-specific osteoporosis cases. By Gender • Male: Rising awareness increasing diagnosis among aging men. • Female: Largest patient population due to menopause-related risks. By Mechanism Action • Antiresorptive: Slows bone breakdown and mineral loss effectively. • Anabolic: Encourages bone growth and density improvement. By Distribution Channel • Retail Pharmacies: Major source for routine osteoporosis medications. • Hospital Pharmacies: Essential for advanced therapy distribution and monitoring. • Online: Growing digital access improving medication convenience. While North America leads the osteoporosis market worldwide owing to well-developed healthcare system, large aging population, and high level of bone health awareness, Europe continues to show considerable growth mainly due to an increase in fragility fracture cases and a growing elderly population. The Asia-Pacific region is the fastest-growing market on account of rapid urbanization, enhanced healthcare facilities, and an increase in the healthcare expenditure of the middle class, whereas South America and the Middle East & Africa are likely to grow steadily through healthcare modernization and economic diversification activities. Strategic Biosimilar Expansion In June 2025, Sandoz Group AG augmented its osteoporosis lineup by launching WYOST and Jubbonti, the first FDA-approved interchangeable denosumab biosimilars in the U.S. The launch enables more people suffering from osteoporosis and cancer-related skeletal complications to get affordable treatment. Advanced Treatment Potential Sclerostin inhibitors are disrupting the osteoporosis market with their immense possibilities as they can treat high-risk patients with severe bone loss and history of fractures efficiently. These drugs simultaneously stimulate bone formation and reduce bone resorption that makes them highly effective as compared to traditional anabolic therapies. Key Report Attributes • Market Size 2025: USD 14,956.06 Million • Market Size 2035: USD 28,335.59 Million • CAGR (2025-2035): 6.51% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Drug Class: Branded - 6.08%, Generic - 7.13%. • By Type: Bisphosphonates - 7.01%, Parathyroid Hormone Therapy - 6.52%. • By Route of Administration: Oral - 5.98%, Injectable - 6.71%. • By Application: Primary Osteoporosis - 6.70%, Secondary Osteoporosis - 5.49%. • By Gender: Male - 4.88%, Female - 7.06%. • By Mechanism Action: Antiresorptive - 6.90%, Anabolic - 5.53%. • By Distribution Channel: Retail Pharmacies - 6.73%, Hospital Pharmacies - 5.85%.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ........................................... 22 1.1 Overview .......................................... 22 1.2 MARKET ATTRACTIVENESS ANALYSIS ..................................... 23 1.3 GLOBAL OSTEOPOROSIS MARKET, BY DRUG CLASS................ 24 1.4 GLOBAL OSTEOPOROSIS MARKET, BY TYPE ............................ 25 1.5 GLOBAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION ................................. 26 1.6 GLOBAL OSTEOPOROSIS MARKET, BY APPLICATION .............. 27 1.7 GLOBAL OSTEOPOROSIS MARKET, BY GENDER ....................... 28 1.8 GLOBAL OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION ....................................... 29 1.9 GLOBAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL ....................................... 30 1.10 GLOBAL OSTEOPOROSIS MARKET, BY REGION ........................ 31 2 MARKET INTRODUCTION ....................................... 33 2.1 DEFINITION ..................................... 33 2.2 SCOPE OF THE STUDY .................... 33 2.3 Research Objective ......................... 33 2.4 MARKET STRUCTURE ..................... 34 3 RESEARCH METHODOLOGY ................................. 35 3.1 Overview .......................................... 35 3.2 DATA flow ....................................... 37 3.2.1 DATA MINING PROCESS ........ 37 3.3 Purchased Database: ...................... 38 3.4 Secondary Sources: ........................ 39 3.4.1 SECONDARY RESEARCH DATA FLOW: ............................. 40 3.5 Primary Research: ........................... 41 3.5.1 PRIMARY RESEARCH DATA FLOW: .................................. 42 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED................................. 43 3.6 Approaches for market size estimation: .................................... 44 3.6.1 REVENUE ANALYSIS APPROACH ...................................... 44 3.7 Data forecasting .............................. 45 3.7.1 DATA FORECASTING TYPE ............................................... 45 3.8 Data modeling ................................. 46 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................ 46 3.8.2 DATA MODELING: ................... 47 3.9 Teams and Analyst Contribution ..... 49 4 MARKET DYNAMICS ............................................... 51 4.1 INTRODUCTION ............................... 51 4.2 Drivers ............................................. 52 4.2.1 AGING GLOBAL DEMOGRAPHICS ..................................... 52 4.2.2 TRANSITION TO HIGH-EFFICACY BIOLOGICS .................. 52 4.2.3 INCREASED POSTMENOPAUSAL AWARENESS ................ 53 4.2.4 ADVANCEMENTS IN INJECTABLE FORMULATIONS ........ 53 4.3 Restraints ........................................ 54 4.3.1 SIDE EFFECTS AND SAFETY CONCERNS ......................... 54 4.3.2 POOR MEDICATION ADHERENCE ..................................... 55 4.3.3 PATENT EXPIRY AND GENERIC PRICE PRESSURE ........... 55 4.4 Opportunities ................................... 56 4.4.1 GROWTH IN SCLEROSTIN INHIBITORS ............................ 56 4.4.2 DEVELOPMENT OF NOVEL MECHANISM-BASED THERAPIES .................................... 57 5 MARKET FACTOR ANALYSIS ................................. 58 5.1 Regulatory Environment & Compliance ...................................... 58 5.2 Technological Trends & Innovation ............................................ 59 5.3 Patient Demographics & Disease Burdens ................................. 60 5.4 Pricing Analysis & Reimbursement Dynamics ........................... 60 5.4.1 PRICING ANALYSIS ................ 60 5.4.2 REIMBURSEMENT DYNAMICS .......................................... 61 5.5 Market Entry & Exit Barriers ............ 62 5.5.1 BARRIERS TO ENTRY ............. 62 5.5.2 BARRIERS TO EXIT ................. 62 5.6 Partnerships & Collaborations ........ 63 5.7 Consumer & Healthcare Provider Preferences .......................... 64 5.7.1 CONSUMER PREFERENCES .............................................. 64 5.7.2 HEALTHCARE PROVIDER PREFERENCES ......................... 64 5.8 PESTLE ANALYSIS .......................... 65 5.8.1 POLITICAL FACTORS ............. 65 5.8.2 ECONOMIC FACTORS ............ 65 5.8.3 SOCIAL FACTORS ................... 65 5.8.4 TECHNOLOGICAL FACTORS ............................................. 66 5.8.5 LEGAL FACTORS .................... 66 5.8.6 ENVIRONMENTAL FACTORS ............................................ 66 5.9 Porter's Five Forces Model.............. 67 5.9.1 THREAT OF NEW ENTRANTS ............................................ 67 5.9.2 BARGAINING POWER OF SUPPLIERS ............................... 68 5.9.3 THREAT OF SUBSTITUTES ..... 68 5.9.4 BARGAINING POWER OF BUYERS .................................... 68 5.9.5 INTENSITY OF RIVALRY ......... 68 5.10 Product Pipeline Analysis ................ 69 5.11 Case Study Analysis ........................ 69 5.12 Investment & Funding Scenarios ............................................... 70 5.13 Post-Market Surveillance & Safety Data..................................... 70 5.14 disease overview ............................. 71 5.15 diagnosis ......................................... 72 5.16 CURRENT TREATMENT .................. 73 6 GLOBAL OSTEOPOROSIS MARKET, BY DRUG CLASS ................................. 76 6.1 Overview .......................................... 76 7 GLOBAL OSTEOPOROSIS MARKET, BY TYPE ..... 78 7.1 Overview .......................................... 78 8 GLOBAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION ...... 81 8.1 Overview .......................................... 81 9 GLOBAL OSTEOPOROSIS MARKET, BY APPLICATION ................................. 83 9.1 Overview .......................................... 83 10 GLOBAL OSTEOPOROSIS MARKET, BY GENDER ......................................... 85 10.1 Overview .......................................... 85 11 GLOBAL OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION .............. 87 11.1 Overview .......................................... 87 12 GLOBAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL ............. 89 12.1 Overview .......................................... 89 13 GLOBAL OSTEOPOROSIS MARKET, BY REGION ........................................... 91 13.1 Overview .......................................... 91 13.2 NORTH AMERICA ............................ 92 13.2.1 US ........................................... 97 13.2.2 CANADA ................................. 100 13.3 EUROPE ........................................... 103 13.3.1 GERMANY ............................... 108 13.3.2 UK ........................................... 111 13.3.3 FRANCE .................................. 114 13.3.4 NETHERLANDS ...................... 117 13.3.5 ITALY ...................................... 120 13.3.6 SPAIN ..................................... 123 13.3.7 REST OF EUROPE ................... 126 13.4 asia-pacific ...................................... 129 13.4.1 CHINA ..................................... 135 13.4.2 INDIA ...................................... 138 13.4.3 JAPAN .................................... 141 13.4.4 SOUTH KOREA ....................... 144 13.4.5 MALAYSIA .............................. 147 13.4.6 THAILAND .............................. 150 13.4.7 INDONESIA ............................. 153 13.4.8 REST OF ASIA-PACIFIC .......... 156 13.5 LATIN AMERICA .............................. 159 13.5.1 BRAZIL .................................... 164 13.5.2 MEXICO .................................. 167 13.5.3 ARGENTINA ............................ 170 13.5.4 REST OF LATIN AMERICA ...... 173 13.6 middle east & africa ........................ 176 13.6.1 GCC COUNTRIES .................... 181 13.6.2 SOUTH AFRICA ....................... 184 13.6.3 REST OF MIDDLE EAST & AFRICA ..................................... 187 14 COMPETITIVE LANDSCAPE ................................... 191 14.1 Introduction ..................................... 191 14.2 Market Share Analysis, 2025 ........... 191 14.3 competitor dashboard ..................... 192 14.4 Public Players Stock Summary ....... 193 14.5 Comparative Analysis: Key Players Financial ............................ 193 14.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ....................... 194 14.6.1 PRODUCT LAUNCH ................ 194 14.6.2 CLINICAL STUDY .................... 194 14.6.3 RELAUNCH ............................. 194 14.6.4 REGULATORY APPROVAL ...... 195 14.6.5 PARTNERSHIP ........................ 195 15 COMPANY PROFILES ............................................. 196 15.1 Amgen Inc. ...................................... 196 15.1.1 COMPANY OVERVIEW ............ 196 15.1.2 FINANCIAL OVERVIEW ........... 197 15.1.3 PRODUCTS OFFERED ............. 197 15.1.4 KEY DEVELOPMENTS ............. 198 15.1.5 SWOT ANALYSIS .................... 198 15.1.6 KEY STRATEGIES ................... 198 15.2 Pfizer Inc. ........................................ 199 15.2.1 COMPANY OVERVIEW ............ 199 15.2.2 FINANCIAL OVERVIEW ........... 200 15.2.3 PRODUCTS OFFERED ............. 201 15.2.4 KEY DEVELOPMENTS ............. 201 15.2.5 SWOT ANALYSIS .................... 202 15.2.6 KEY STRATEGIES ................... 202 15.3 SANDOZ GROUP AG ........................ 203 15.3.1 COMPANY OVERVIEW ............ 203 15.3.2 FINANCIAL OVERVIEW ........... 204 15.3.3 PRODUCTS OFFERED ............. 204 15.3.4 KEY DEVELOPMENTS ............. 205 15.3.5 KEY STRATEGIES ................... 205 15.4 NOVARTIS AG.................................. 206 15.4.1 COMPANY OVERVIEW ............ 206 15.4.2 FINANCIAL OVERVIEW ........... 207 15.4.3 PRODUCTS OFFERED ............. 208 15.4.4 KEY DEVELOPMENTS ............. 208 15.4.5 KEY STRATEGIES ................... 208 15.5 Eli Lilly and Company ...................... 209 15.5.1 COMPANY OVERVIEW ............ 209 15.5.2 FINANCIAL OVERVIEW ........... 210 15.5.3 PRODUCTS OFFERED ............. 211 15.5.4 KEY DEVELOPMENTS ............. 211 15.5.5 KEY STRATEGIES ................... 211 15.6 Teva Pharmaceutical Industries Ltd. ......................................... 212 15.6.1 COMPANY OVERVIEW ............ 212 15.6.2 FINANCIAL OVERVIEW ........... 213 15.6.3 PRODUCTS OFFERED ............. 214 15.6.4 KEY DEVELOPMENTS ............. 214 15.6.5 KEY STRATEGIES ................... 214 15.7 AbbVie Inc. ...................................... 215 15.7.1 COMPANY OVERVIEW ............ 215 15.7.2 FINANCIAL OVERVIEW ........... 215 15.7.3 PRODUCTS OFFERED ............. 217 15.7.4 KEY DEVELOPMENTS ............. 217 15.7.5 SWOT ANALYSIS .................... 217 15.7.6 KEY STRATEGIES ................... 218 15.8 Radius Health, Inc. .......................... 219 15.8.1 COMPANY OVERVIEW ............ 219 15.8.2 FINANCIAL OVERVIEW ........... 220 15.8.3 PRODUCTS OFFERED ............. 220 15.8.4 KEY DEVELOPMENTS ............. 220 15.8.5 SWOT ANALYSIS .................... 221 15.8.6 KEY STRATEGIES ................... 222 15.9 CIPLA ............................................... 223 15.9.1 COMPANY OVERVIEW ............ 223 15.9.2 FINANCIAL OVERVIEW ........... 224 15.9.3 PRODUCTS OFFERED ............. 225 15.9.4 KEY DEVELOPMENTS ............. 225 15.9.5 SWOT ANALYSIS .................... 225 15.9.6 KEY STRATEGIES ................... 226 15.10 Organon ........................................... 227 15.10.1 COMPANY OVERVIEW ............ 227 15.10.2 FINANCIAL OVERVIEW ........... 228 15.10.3 PRODUCTS OFFERED ............. 229 15.10.4 KEY DEVELOPMENTS ............. 229 15.10.5 KEY STRATEGIES ................... 229 16 DATA CITATIONS .......... 230
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 48 TABLE 2 PRODUCT PIPELINE 69 TABLE 3 GLOBAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 77 TABLE 4 GLOBAL OSTEOPOROSIS MARKET, BY TYPE, 2019-2035 (USD MILLION) 79 TABLE 5 GLOBAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 82 TABLE 6 GLOBAL OSTEOPOROSIS MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 84 TABLE 7 GLOBAL OSTEOPOROSIS MARKET, BY GENDER, 2019-2035 (USD MILLION) 86 TABLE 8 GLOBAL OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD MILLION) 88 TABLE 9 GLOBAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 90 TABLE 10 GLOBAL OSTEOPOROSIS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 91 TABLE 11 NORTH AMERICA OSTEOPOROSIS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 93 TABLE 12 NORTH AMERICA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 94 TABLE 13 NORTH AMERICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 94 TABLE 14 NORTH AMERICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 95 TABLE 15 NORTH AMERICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 95 TABLE 16 NORTH AMERICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 95 TABLE 17 NORTH AMERICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 96 TABLE 18 NORTH AMERICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 96 TABLE 19 US: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 97 TABLE 20 US: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 97 TABLE 21 US: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 98 TABLE 22 US: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 98 TABLE 23 US: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 98 TABLE 24 US: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 99 TABLE 25 US: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 99 TABLE 26 CANADA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 100 TABLE 27 CANADA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 100 TABLE 28 CANADA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 101 TABLE 29 CANADA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 101 TABLE 30 CANADA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 101 TABLE 31 CANADA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 102 TABLE 32 CANADA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 102 TABLE 33 EUROPE OSTEOPOROSIS MARKET, BY COUNTRY, 2019-2036 (USD MILLION) 104 TABLE 34 EUROPE: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 105 TABLE 35 EUROPE: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 105 TABLE 36 EUROPE: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 106 TABLE 37 EUROPE: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 106 TABLE 38 EUROPE: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 106 TABLE 39 EUROPE: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 107 TABLE 40 EUROPE: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 107 TABLE 41 GERMANY: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 108 TABLE 42 GERMANY: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 108 TABLE 43 GERMANY: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 109 TABLE 44 GERMANY: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 109 TABLE 45 GERMANY: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 109 TABLE 46 GERMANY: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 110 TABLE 47 GERMANY: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 110 TABLE 48 UK: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 111 TABLE 49 UK: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 111 TABLE 50 UK: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 112 TABLE 51 UK: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 112 TABLE 52 UK: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 112 TABLE 53 UK: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 113 TABLE 54 UK: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 113 TABLE 55 FRANCE: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 114 TABLE 56 FRANCE: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 114 TABLE 57 FRANCE: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 115 TABLE 58 FRANCE: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 115 TABLE 59 FRANCE: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 115 TABLE 60 FRANCE: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 116 TABLE 61 FRANCE: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 116 TABLE 62 NETHERLANDS: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 117 TABLE 63 NETHERLANDS: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 117 TABLE 64 NETHERLANDS: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 118 TABLE 65 NETHERLANDS: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 118 TABLE 66 NETHERLANDS: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 118 TABLE 67 NETHERLANDS: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 119 TABLE 68 NETHERLANDS: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 119 TABLE 69 ITALY: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 120 TABLE 70 ITALY: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 120 TABLE 71 ITALY: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 121 TABLE 72 ITALY: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 121 TABLE 73 ITALY: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 121 TABLE 74 ITALY: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 122 TABLE 75 ITALY: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 122 TABLE 76 SPAIN: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 123 TABLE 77 SPAIN: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 123 TABLE 78 SPAIN: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 124 TABLE 79 SPAIN: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 124 TABLE 80 SPAIN: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 124 TABLE 81 SPAIN: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 125 TABLE 82 SPAIN: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 125 TABLE 83 REST OF EUROPE: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 126 TABLE 84 REST OF EUROPE: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 126 TABLE 85 REST OF EUROPE: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 127 TABLE 86 REST OF EUROPE: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 127 TABLE 87 REST OF EUROPE: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 127 TABLE 88 REST OF EUROPE: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 128 TABLE 89 REST OF EUROPE: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 128 TABLE 90 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 130 TABLE 91 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 131 TABLE 92 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 132 TABLE 93 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 132 TABLE 94 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 133 TABLE 95 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 133 TABLE 96 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 133 TABLE 97 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 134 TABLE 98 CHINA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 135 TABLE 99 CHINA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 135 TABLE 100 CHINA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 136 TABLE 101 CHINA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 136 TABLE 102 CHINA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 136 TABLE 103 CHINA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 137 TABLE 104 CHINA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 137 TABLE 105 INDIA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 138 TABLE 106 INDIA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 138 TABLE 107 INDIA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 139 TABLE 108 INDIA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 139 TABLE 109 INDIA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 139 TABLE 110 INDIA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 140 TABLE 111 INDIA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 140 TABLE 112 JAPAN: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 141 TABLE 113 JAPAN: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 141 TABLE 114 JAPAN: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 142 TABLE 115 JAPAN: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 142 TABLE 116 JAPAN: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 142 TABLE 117 JAPAN: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 143 TABLE 118 JAPAN: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 143 TABLE 119 SOUTH KOREA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 144 TABLE 120 SOUTH KOREA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 144 TABLE 121 SOUTH KOREA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 145 TABLE 122 SOUTH KOREA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 145 TABLE 123 SOUTH KOREA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 145 TABLE 124 SOUTH KOREA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 146 TABLE 125 SOUTH KOREA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 146 TABLE 126 MALAYSIA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 147 TABLE 127 MALAYSIA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 147 TABLE 128 MALAYSIA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 148 TABLE 129 MALAYSIA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 148 TABLE 130 MALAYSIA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 148 TABLE 131 MALAYSIA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 149 TABLE 132 MALAYSIA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 149 TABLE 133 THAILAND: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 150 TABLE 134 THAILAND: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 150 TABLE 135 THAILAND: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 151 TABLE 136 THAILAND: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 151 TABLE 137 THAILAND: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 151 TABLE 138 THAILAND: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 152 TABLE 139 THAILAND: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 152 TABLE 140 INDONESIA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 153 TABLE 141 INDONESIA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 153 TABLE 142 INDONESIA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 154 TABLE 143 INDONESIA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 154 TABLE 144 INDONESIA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 154 TABLE 145 INDONESIA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 155 TABLE 146 INDONESIA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 155 TABLE 147 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 156 TABLE 148 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 156 TABLE 149 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 157 TABLE 150 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 157 TABLE 151 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 157 TABLE 152 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 158 TABLE 153 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 158 TABLE 154 LATIN AMERICA: HYALURONIC ACID, BY COUNTRY, 2019-2035 (USD MILLION) 160 TABLE 155 LATIN AMERICA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 161 TABLE 156 LATIN AMERICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 161 TABLE 157 LATIN AMERICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 162 TABLE 158 LATIN AMERICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 162 TABLE 159 LATIN AMERICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 162 TABLE 160 LATIN AMERICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 163 TABLE 161 LATIN AMERICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 163 TABLE 162 BRAZIL: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 164 TABLE 163 BRAZIL: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 164 TABLE 164 BRAZIL: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 165 TABLE 165 BRAZIL: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 165 TABLE 166 BRAZIL: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 165 TABLE 167 BRAZIL: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 166 TABLE 168 BRAZIL: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 166 TABLE 169 MEXICO: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 167 TABLE 170 MEXICO: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 167 TABLE 171 MEXICO: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 168 TABLE 172 MEXICO: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 168 TABLE 173 MEXICO: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 168 TABLE 174 MEXICO: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 169 TABLE 175 MEXICO: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 169 TABLE 176 ARGENTINA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 170 TABLE 177 ARGENTINA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 170 TABLE 178 ARGENTINA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 171 TABLE 179 ARGENTINA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 171 TABLE 180 ARGENTINA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 171 TABLE 181 ARGENTINA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 172 TABLE 182 ARGENTINA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 172 TABLE 183 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 173 TABLE 184 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 173 TABLE 185 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 174 TABLE 186 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 174 TABLE 187 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 174 TABLE 188 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 175 TABLE 189 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 175 TABLE 190 MIDDLE EAST & AFRICA: HYALURONIC ACID, BY COUNTRY, 2019-2035 (USD MILLION) 177 TABLE 191 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 178 TABLE 192 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 178 TABLE 193 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 179 TABLE 194 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 179 TABLE 195 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 179 TABLE 196 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 180 TABLE 197 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 180 TABLE 198 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 181 TABLE 199 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 181 TABLE 200 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 182 TABLE 201 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 182 TABLE 202 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 182 TABLE 203 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 183 TABLE 204 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 183 TABLE 205 SOUTH AFRICA : OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 184 TABLE 206 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 184 TABLE 207 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 185 TABLE 208 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 185 TABLE 209 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 185 TABLE 210 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 186 TABLE 211 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 186 TABLE 212 REST OF MEA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 187 TABLE 213 REST OF MEA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 187 TABLE 214 REST OF MEA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 188 TABLE 215 REST OF MEA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 188 TABLE 216 REST OF MEA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 188 TABLE 217 REST OF MEA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 189 TABLE 218 REST OF MEA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 189 TABLE 219 PRODUCT LAUNCH 194 TABLE 220 CLINICAL STUDY 194 TABLE 221 RELAUNCH 194 TABLE 222 REGULATORY APPROVAL 195 TABLE 223 PARTNERSHIP 195 TABLE 224 AMGEN INC.: PRODUCTS OFFERED 197 TABLE 225 AMGEN INC.: KEY DEVELOPMENTS 198 TABLE 226 PFIZER INC.: PRODUCTS OFFERED 201 TABLE 227 PFIZER INC.: KEY DEVELOPMENTS 201 TABLE 228 SANDOZ GROUP AG: PRODUCTS OFFERED 204 TABLE 229 SANDOZ GROUP AG: KEY DEVELOPMENTS 205 TABLE 230 NOVARTIS AG: PRODUCTS OFFERED 208 TABLE 231 ELI LILLY AND COMPANY: PRODUCTS OFFERED 211 TABLE 232 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED 214 TABLE 233 ABBVIE, INC.: PRODUCTS OFFERED 217 TABLE 234 RADIUS HEALTH, INC.: PRODUCTS OFFERED 220 TABLE 235 RADIUS HEALTH, INC.: KEY DEVELOPMENT 220 TABLE 236 CIPLA: PRODUCTS OFFERED 225 TABLE 237 ORGANON: PRODUCTS OFFERED 229 TABLE 238 ORGANON: KEY DEVELOPMENT 229 LIST OF FIGURES FIGURE 1 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL OSTEOPOROSIS MARKET, 2025 23 FIGURE 2 GLOBAL OSTEOPOROSIS MARKET ANALYSIS, BY DRUG CLASS, 2025 (USD MILLION AND %) 24 FIGURE 3 GLOBAL OSTEOPOROSIS MARKET ANALYSIS, BY TYPE, 2025 (USD MILLION AND %) 25 FIGURE 4 GLOBAL OSTEOPOROSIS MARKET ANALYSIS, BY ROUTE OF ADMINISTRATION, 2025 (USD MILLION AND %) 26 FIGURE 5 GLOBAL OSTEOPOROSIS MARKET ANALYSIS, BY APPLICATION, 2025 (USD MILLION AND %) 27 FIGURE 6 GLOBAL OSTEOPOROSIS MARKET ANALYSIS, BY GENDER, 2025 (USD MILLION AND %) 28 FIGURE 7 GLOBAL OSTEOPOROSIS MARKET ANALYSIS, BY MECHANISM OF ACTION, 2025 (USD MILLION AND %) 29 FIGURE 8 GLOBAL OSTEOPOROSIS MARKET ANALYSIS, BY DISTRIBUTION CHANNEL, 2025 (USD MILLION AND %) 30 FIGURE 9 GLOBAL OSTEOPOROSIS MARKET ANALYSIS, BY REGION, 2025 (USD MILLION AND %) 31 FIGURE 1 GLOBAL OSTEOPOROSIS MARKET: STRUCTURE 34 FIGURE 2 GLOBAL OSTEOPOROSIS MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2036) 51 FIGURE 3 GLOBAL OSTEOPOROSIS MARKET DRIVER: IMPACT ANALYSIS 54 FIGURE 4 GLOBAL OSTEOPOROSIS MARKET RESTRAINT: IMPACT ANALYSIS 56 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL OSTEOPOROSIS TREATMENT MARKET 67 FIGURE 6 GLOBAL OSTEOPOROSIS MARKET, DRUG CLASS SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 76 FIGURE 7 GLOBAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2025 & 2035 (USD MILLION) 76 FIGURE 8 GLOBAL OSTEOPOROSIS MARKET SHARE (%), BY DRUG CLASS, 2025 77 FIGURE 9 GLOBAL OSTEOPOROSIS MARKET, TYPE SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 78 FIGURE 10 GLOBAL OSTEOPOROSIS MARKET, BY TYPE, 2025 & 2035 (USD MILLION) 79 FIGURE 11 GLOBAL OSTEOPOROSIS MARKET SHARE (%), BY TYPE, 2025 80 FIGURE 12 GLOBAL OSTEOPOROSIS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 81 FIGURE 13 GLOBAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2025 & 2035 (USD MILLION) 82 FIGURE 14 GLOBAL OSTEOPOROSIS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2025 82 FIGURE 15 GLOBAL OSTEOPOROSIS MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 83 FIGURE 16 GLOBAL OSTEOPOROSIS MARKET, BY APPLICATION, 2025 & 2035 (USD MILLION) 83 FIGURE 17 GLOBAL OSTEOPOROSIS MARKET SHARE (%), BY APPLICATION, 2025 84 FIGURE 18 GLOBAL OSTEOPOROSIS MARKET, GENDER SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 85 FIGURE 19 GLOBAL OSTEOPOROSIS MARKET, BY GENDER, 2025 & 2035 (USD MILLION) 85 FIGURE 20 GLOBAL OSTEOPOROSIS MARKET SHARE (%), BY GENDER, 2025 86 FIGURE 21 GLOBAL OSTEOPOROSIS MARKET, MECHANISM OF ACTION SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 87 FIGURE 22 GLOBAL OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2025 & 2035 (USD MILLION) 87 FIGURE 23 GLOBAL OSTEOPOROSIS MARKET SHARE (%), BY MECHANISM OF ACTION, 2025 88 FIGURE 24 GLOBAL OSTEOPOROSIS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 89 FIGURE 25 GLOBAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2025 & 2035 (USD MILLION) 89 FIGURE 26 GLOBAL OSTEOPOROSIS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2025 90 FIGURE 27 GLOBAL MARKET ANALYSIS: OSTEOPOROSISS MARKET, 2019-2035 (USD MILLION) 91 FIGURE 28 GLOBAL OSTEOPOROSIS MARKET, BY REGION, 2025 (% SHARE) 92 FIGURE 29 NORTH AMERICA MARKET: SWOT ANALYSIS 92 FIGURE 30 NORTH AMERICA OSTEOPOROSIS MARKET, BY REGION, 2025 & 2036 (USD MILLION) 93 FIGURE 31 NORTH AMERICA OSTEOPOROSIS MARKET SHARE (%), BY COUNTRY, 2025 93 FIGURE 32 EUROPE MARKET: SWOT ANALYSIS 103 FIGURE 33 EUROPE OSTEOPOROSIS MARKET, BY REGION, 2025 & 2036 (USD MILLION) 103 FIGURE 34 EUROPE OSTEOPOROSIS MARKET SHARE (%), BY COUNTRY, 2025 104 FIGURE 35 ASIA-PACIFIC MARKET SWOT ANALYSIS: OSTEOPOROSIS MARKET 129 FIGURE 36 ASIA-PACIFIC: OSTEOPOROSIS MARKET SHARE, BY COUNTRY, 2025 & 2035 (USD MILLION) 130 FIGURE 37 ASIA-PACIFIC: OSTEOPOROSIS MARKET SHARE, BY COUNTRY, 2025 (%) 131 FIGURE 38 LATIN AMERICA MARKET SWOT ANALYSIS: OSTEOPOROSIS MARKET 159 FIGURE 39 LATIN AMERICA: OSTEOPOROSIS MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 159 FIGURE 40 LATIN AMERICA: OSTEOPOROSIS MARKET SHARE (%), BY COUNTRY, 2025 160 FIGURE 41 MIDDLE EAST AND AFRICA MARKET SWOT ANALYSIS: OSTEOPOROSIS MARKET 176 FIGURE 42 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 176 FIGURE 43 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET SHARE (%), BY COUNTRY, 2025 177 FIGURE 44 GLOBAL OSTEOPOROSIS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 191 FIGURE 45 COMPETITOR DASHBOARD: GLOBAL OSTEOPOROSIS MARKET 192 FIGURE 46 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 197 FIGURE 47 AMGEN INC.: SWOT ANALYSIS 198 FIGURE 48 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 200 FIGURE 49 PFIZER INC.: SWOT ANALYSIS 202 FIGURE 50 SANDOZ GROUP AG: FINANCIAL OVERVIEW SNAPSHOT 204 FIGURE 51 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 207 FIGURE 52 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 210 FIGURE 53 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 213 FIGURE 54 ABBVIE, INC.: FINANCIAL OVERVIEW SNAPSHOT 215 FIGURE 55 ABBVIE, INC.: SWOT ANALYSIS 217 FIGURE 56 RADIUS HEALTH, INC.:SWOT ANALYSIS 221 FIGURE 57 CIPLA: FINANCIAL OVERVIEW SNAPSHOT 224 FIGURE 58 CIPLA: SWOT ANALYSIS 225 FIGURE 59 ORGANON: FINANCIAL OVERVIEW SNAPSHOT 228

提及公司

Amgen Inc.Pfizer Inc.Sandoz Group AgNovartis AGEli Lilly And CompanyTeva Pharmaceutical Industries Ltd.AbbvieInc.Radius HealthInc.CiplaOrganon

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們